ABSTRACT

IMMEDIATE MANAGEMENT Most patients undergoing allogeneic HSCT receive GVHD prophylaxis in the form of ciclosporin or tacrolimus. Variable T cell depletion of the graft is also commonly used to reduce graft-versus-host reactions.